Stem cell research boosted
Future Science Group is delighted to announce the launch of its new journal Regenerative Medicine published under the aegis of Senior Editor Dr Stephen Minger of King’s College London. Regenerative Medicine provides a forum to address the important challenges and advances in stem cell research and regenerative medicine, delivering essential information in concise, clear and attractive article formats. The journal is published by Future Medicine, one of the Future Science Group companies.
Regenerative Medicine is published bimonthly in print and online formats and offers review articles, primary research, editorials, technology reports, interviews, perspectives and a variety of added-value content. Rigorous peer review and rapid publication ensure that only the best quality and pertinent research is published in a timely manner. The electronic version of Regenerative Medicine is available from the Future Medicine website (www.futuremedicine.com) and from the Ingenta aggregation service (www.ingentaconnect.com).
Elisa Manzotti, Editorial Director of Future Medicine commented; “In recent years we have seen substantial developments in our knowledge and understanding of stem cell biology and regenerative medicine. Nevertheless, in many respects, the field is still in its infancy. The next few decades will unveil the true potential of this emerging specialty. Regenerative Medicine will provide a critical overview of these advances as they unfold and explore their potential relevance in the clinical setting.”
Senior Editor Dr Stephen Minger is Director of the Stem Cell Biology Laboratory at the Wolfson Centre for Age Related Diseases, King’s College London, UK. He is assisted by an internationally acclaimed editorial advisory board comprising more than 70 leading experts.
Dr Minger commented; “The field of regenerative medicine and stem cell biology has become one of the hottest areas in contemporary science. The launch of Regenerative Medicine, as the pre-eminent, pioneering, international scientific publication in translational and cellular medicine is extremely timely.” He continued, “This is the first international journal devoted to the emerging field of regenerative medicine and stem cell biology. We have assembled an outstanding group of scientists as members of the editorial board and with their help we will publish the most up-to-date research, reviews scientific and clinical meeting reports, technical updates and editorials”.
Dr Minger, together with Dr Chris Mason from University College London, has also recently initiated the London Regenerative Medicine Network (LRMN). With a membership of over 1300 basic scientists, clinicians, lawyers, investors and members of the regulatory and funding bodies, monthly LRMN meetings provide highly active and collaborative symposium for current research related to regenerative medicine.
Regenerative Medicine is available now in both print and online formats. Free trial access to the first issue is available on request. Applicants should contact Stephen Galt, Sales Manager, Future Science Group at info@futuremedicine.com or visit www.futuremedicine.com.